Please login to the form below

Not currently logged in
Email:
Password:

DH appoints chair of Monitor

The UK's Department of Health has appointed Dr David Bennett as chair of Monitor, the independent regulator of foundation trusts

The UK's Department of Health (DH) has appointed Dr David Bennett as chair of Monitor, the independent regulator of foundation trusts.

Dr Bennett currently holds the position of interim chief executive with the body, and will take over the role of chair from Steve Bundred.

The role of Monitor is proposed to change under the Health and Social Care Bill, with plans for the body to become economic regulator for all providers of health and adult social care services by 2013.

In this new role, Monitor would regulate pricing for NHS services; promote competition in healthcare services where appropriate; and to support GP consortia in ensuring essential services are maintained.

Dr Bennett, whose previous roles include non-political chief policy advisor to former Prime Minister Tony Blair and director at McKinsey & Co, described the successful implementation of the reforms as 'critical' with Monitor to play a key role in ensuring quality care.

Health Secretary Andrew Lansley commented on the appointment: "The new economic regulator will have a significantly different set of responsibilities from Monitor in its current form and, with his wealth of experience, I am confident that David will successfully lead the organisation through the changes ahead."

21st February 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics